Related Experiment Videos
Clenbuterol ("Spiropent'): a long-acting bronchodilator
Current Medical Research and Opinion
|January 1, 1982
Summary
Clenbuterol demonstrated superior efficacy over aminophylline in managing asthma symptoms, significantly reducing daytime and nighttime wheezing. This study highlights clenbuterol as a more effective treatment for reversible airways obstruction.
Area of Science:
- Pulmonology
- Pharmacology
Background:
- Asthma and reversible airways obstruction are common respiratory conditions.
- Effective bronchodilator therapy is crucial for symptom management.
Purpose of the Study:
- To compare the efficacy of clenbuterol and aminophylline in patients with asthma.
- To evaluate the impact of these drugs on wheezing and peak expiratory flow rate (PEFR).
Main Methods:
- A double-blind, crossover trial involving 47 asthma patients.
- Patients received either clenbuterol or aminophylline for 4-week periods after a 2-week control phase.
- Daily symptom severity and PEFR (morning and night) were recorded.
Main Results:
- Both drugs reduced daytime wheeze significantly in the initial 4 weeks.
- Clenbuterol provided further significant reductions in daytime wheeze and significantly reduced nighttime wheeze.
- Clenbuterol administration led to significant increases in morning and nighttime PEFR.
Conclusions:
- Clenbuterol showed greater effectiveness than aminophylline in alleviating asthma symptoms, particularly nighttime wheezing.
- Clenbuterol appears to be a more beneficial treatment option for patients with asthma and reversible airways obstruction.